Trigger-responsive engineered-nanocarriers and image-guided theranostics for rheumatoid arthritis

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Rheumatology

Background:

• Rheumatoid Arthritis (RA) affects 1% of the global population, causing joint destruction and disability.
• Current RA therapies have limitations including non-responsiveness and side effects.
• Conventional nanocarriers (CNCs) improve efficacy but suffer from uncontrolled drug release.

Purpose of the Study:

• To review advancements in trigger-responsive and image-guided theranostic engineered nanocarriers (ENCs) for RA treatment.
• To explore design strategies, mechanisms, and translational perspectives of these novel ENCs.
• To highlight the potential of ENCs in overcoming limitations of conventional nanocarrier systems.

Main Methods:

• Review of recent literature on engineered nanocarriers for RA.
• Analysis of trigger-responsive mechanisms (endogenous and exogenous).
• Examination of image-guided theranostic approaches for site-specific drug delivery.

Main Results:

• ENCs enable on-demand drug release triggered by specific conditions in arthritic joints (e.g., pH, enzymes, light).
• Image-guided ENCs allow simultaneous monitoring and targeted therapeutic action.
• ENCs demonstrate potential for reduced off-target toxicity and improved therapeutic outcomes.

Conclusions:

• Trigger-responsive and image-guided theranostic ENCs represent a promising frontier in RA treatment.
• These advanced nanocarriers offer precise control over drug release and targeted delivery.
• Further research and development are crucial for the clinical translation of ENCs in managing rheumatoid arthritis.